Medsens AB – exact real time prostate cancer diagnosis

By combining two different methods, Medsens AB is aiming at offering a whole new tool for realtime microdiagnostics during prostate cancer surgery. The company's instrument is far more accurate that the methods used by clinicians today - which could make surginal procedures much more efficient. The project is based on the work of Olof Lindahl och Kerstin Ramser.


Prostate Cancer surgery is not accurate enough

Prostate cancer (PCa) is the fourth most common cancer in both sexes combined and the second most common cancer in men. In Sweden PCa is the most common cancer disease among all, and 9678 men were diagnosed with PCa in 2013 (Cancerfonden).  In 2012, 1.1 million men worldwide were diagnosed with prostate cancer and 307 000 estimated deaths in 2012. The most prevalent curative treatment for PCa is radical prostatectomy (RP). In Europe, RP made up 59 % of the curative treatments in 2000 and in the USA about 70 000 men were offered RP in 2003. 1880 surgical treatments for Prostate cancer is conducted per year in Sweden, 10-20 % of these need chemotherapy afterwards due to that all cancer tissue was not removed.

Our solution - a real-time instrument to increase precision

Our instrument combines two sensor methods into one small probe combining a resonance sensor with a Raman spectroscope, that rapidly can scan the prostate surface during surgery and give the surgeon correct information about correct removal of all cancer tissue. .

An whole new surgical aid to reduce cancer relapse

The instrument will during surgery give information about the localization of suspected cancer tumors by measuring the tissue hardness in prostate and define the molecular content by an optical Raman spectrum. This will give the surgeon the extra information needed to securely remove all tumor cells resulting in an efficient and more accurate removal than before. We will with our instrument reduce the risk of cancer relapse after surgical treatment that will save suffering and substantial cost.

First real-time instrument available in the field

The methods in clinical use today like ultrasound, MRI and histopathology are inexact and/or very expensive, and furthermore cannot be used during surgery, i.e. no method can give rapid information at surgical site.

Patent secured - funds to bring tool to market needed

Supporting data is already provided and published and a patent is approved. A need analysis, market analysis and competition analysis supporting the idea was performed in 2006 and have to be updated.

Umeå Biotech Incubator (UBI)
Box 7995, SE-907 36 Umeå, Sweden
Phone: +46(0)90- 15 49 70